MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing a novel approach to intoxication detection by leveraging artificial intelligence to analyze human voice patterns. In a recent interview on the TechMediaWire Podcast, CEO Justin Hanka outlined the company's plans to commercialize this technology as a scalable, non-invasive alternative to conventional biological sample testing.
The company has built prediction models using over 50 million data points collected through years of clinical research, enabling the identification of indicators associated with alcohol and drug use. According to Hanka, the technology can detect intoxication through speech assessment alone, potentially transforming workplace safety protocols across industries such as mining, aviation, construction, and law enforcement.
MindBio is developing enterprise deployment systems that combine proprietary software with Edge-AI kiosks capable of delivering assessments in less than three seconds. The company expects to begin live workplace testing during the second quarter of 2026. Beyond immediate impairment detection, management sees broader applications for AI-driven voice analytics as a diagnostic tool for identifying physiological and neurological conditions.
The technology addresses limitations of current methods, which often require blood, urine, or saliva samples—processes that can be invasive, time-consuming, and costly. By offering a rapid, non-invasive alternative, MindBio's solution could improve compliance and efficiency in safety-sensitive environments.
For more details, the full interview is available at https://ibn.fm/HJarm. Further information about MindBio can be found in the company's newsroom at https://ibn.fm/MBQIF.
